FTFranziska Cand.Med. Tief

Franziska Cand.Med. Tief

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Franziska Cand.Med. Tief has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of novel second-generation RSV and influenza rapid tests at the point of care

    by Ryan Tuttle, Anja Weick, Wiebke Sabrina Schwarz, Xi Chen, Patrick Obermeier, Lea Seeber, Franziska Tief, Susann Muehlhans, Katharina Karsch, Christian Peiser, et al.


  • Virus Load Kinetics and Resistance Development During Oseltamivir Treatment in Infants and Children Infected With Influenza A(H1N1) 2009 and Influenza B Viruses

    by Barbara Rath, Max von Kleist, Franziska Cand.Med. Tief, Katharina Cand.Med. Karsch, Ewelina Cand.Med. Tuerk, Susann Cand.Med. Muehlhans, Florian Louis, Heino Skopnik, Brunhilde Schweiger, Susanne Duwe

    Background: Infants and small children are the most effective transmitters of influenza, while bearing a high risk of hospitalization and adverse disease outcomes. This study aims to investigate virus load kinetics and resistance development during oseltamivir therapy in infants and children infected with influenza A(H1N1) 2009 and influenza B viruses. Methods: Virus load in nasopharyngeal samples and phenotypic/genotypic neuraminidase inhibitor resistance were determined at baseline, at day 5 and in additional follow-up samples, if available. Patient-specific viral clearance indices CLν(i) were determined along with estimates of the time required to achieve nondetectable virus load. Results: No evidence of baseline oseltamivir resistance was detected in 36 patients infected with influenza A(H1N1) 2009 (n = 27) or influenza B (Victoria, Yamagata; n = 9) before oseltamivir therapy. On average, viral loads were lower for influenza type B (median = 5.9·103/mL) than for drug-resistant (median = 2.6·106/mL) and sensitive A(H1N1) 2009 (median = 4.8·104/mL), P = 0.04 and P = 0.09, respectively. Time required to achieve nondetectable virus load was significantly longer in drug-resistant A(H1N1) 2009 (median 15.4 days) compared with drug-sensitive A(H1N1) 2009 (P = 0.003; median 7.7 days) and drug-sensitive influenza B (P = 0.001; median 5 days). No evidence of viral rebound was observed once viral clearance was achieved. Conclusions: Our data indicate that influenza subtyping in combination with baseline viral load measurements might help to optimize the duration of antiviral therapy in the individual child. Lower than expected virologic response rates in patients without malabsorption or compliance issues may suggest resistance development.